Table 2.
Summary: Nontreponemal Antibodies for Various Stages of Syphilis
Stage of Syphilis | Nontreponemal Test | Sensitivity | Specificity | Quality of Studies |
---|---|---|---|---|
Primary | Serum RPR | 62.5–76.1%a | N/A | High |
Serum VDRL | 62.5–78.4%b | N/A | High | |
Secondary | Serum RPR | 100%c | N/A | High |
Serum VDRL | 100% | N/A | High | |
Early latent | Serum VDRL | 85–100% | N/A | High |
Late latent or unknown duration | Serum RPR | 61% | N/A | High (1 study) |
Serum VDRL | 64% | N/A | High (1 study) | |
Tertiary | Serum VDRL | 47–64% | N/A | Lower (2 studies) |
Neurosyphilis | CSF RPR | 51.5–81.8% | 81.8–100% | High |
CSF VDRL | 49–87.5% | 74–100% | High | |
Ocular | CSF VDRL | 0–50% | N/A | Lower |
Otic | CSF VDRL | 5.5–5.6% | N/A | Lower (2 studies) |
For full references, see the text of the paper and Table 1.
Abbreviations: CSF, cerebrospinal fluid; RPR, rapid plasma reagin; VDRL, venereal disease research laboratory.
a1 high-quality paper reported a sensitivity of 92.7%.
b1 high-quality paper reported a sensitivity of 50%.
c1 high-quality paper reported a sensitivity of 97.2%.